Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey

Thumbnail Image
TÜREL, Özden
Kisa, Adnan
McIntosh, E. David G.
Bakir, Mustafa
Journal Title
Journal ISSN
Volume Title
Research Projects
Organizational Units
Journal Issue
Background: Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent version could at least maintain -standard of care- if not improve it, and that it could be affordable. Objectives and Methods: The aim of this analysis was to assess the potential direct cost-effectiveness of 13-valent PCV in Turkey, a country with a birth cohort of 1.4 million, against a -no vaccine- state, against the default 7-valent PCV state, and against a 10-valent PCV state, using a published cohort model with a 5-year horizon. Results and Conclusions: The cost per life-year gained is below the 1 x per-capita gross domestic product threshold across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.
TÜREL Ö., Kisa A., McIntosh E. D. G. , Bakir M., -Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey-, VALUE IN HEALTH, cilt.16, ss.755-759, 2013
Sustainable Development Goals